115 related articles for article (PubMed ID: 33784495)
1. Structural insights into the function of the catalytically active human Taspase1.
Nagaratnam N; Delker SL; Jernigan R; Edwards TE; Snider J; Thifault D; Williams D; Nannenga BL; Stofega M; Sambucetti L; Hsieh JJ; Flint AJ; Fromme P; Martin-Garcia JM
Structure; 2021 Aug; 29(8):873-885.e5. PubMed ID: 33784495
[TBL] [Abstract][Full Text] [Related]
2. Structural Characterization of the Loop at the Alpha-Subunit C-Terminus of the Mixed Lineage Leukemia Protein Activating Protease Taspase1.
van den Boom J; Trusch F; Hoppstock L; Beuck C; Bayer P
PLoS One; 2016; 11(3):e0151431. PubMed ID: 26974973
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of human Taspase1, a crucial protease regulating the function of MLL.
Khan JA; Dunn BM; Tong L
Structure; 2005 Oct; 13(10):1443-52. PubMed ID: 16216576
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of the catalytically impaired Taspase1 T234V or Taspase1 D233A variants does not have a dominant negative effect in T(4;11) leukemia cells.
Bier C; Hecht R; Kunst L; Scheiding S; Wünsch D; Goesswein D; Schneider G; Krämer OH; Knauer SK; Stauber RH
PLoS One; 2012; 7(5):e34142. PubMed ID: 22570686
[TBL] [Abstract][Full Text] [Related]
5. Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis.
Chen DY; Liu H; Takeda S; Tu HC; Sasagawa S; Van Tine BA; Lu D; Cheng EH; Hsieh JJ
Cancer Res; 2010 Jul; 70(13):5358-67. PubMed ID: 20516119
[TBL] [Abstract][Full Text] [Related]
6. Unraveling the Activation Mechanism of Taspase1 which Controls the Oncogenic AF4-MLL Fusion Protein.
Sabiani S; Geppert T; Engelbrecht C; Kowarz E; Schneider G; Marschalek R
EBioMedicine; 2015 May; 2(5):386-95. PubMed ID: 26137584
[TBL] [Abstract][Full Text] [Related]
7. Taspase1: a 'misunderstood' protease with translational cancer relevance.
Wünsch D; Hahlbrock A; Jung S; Schirmeister T; van den Boom J; Schilling O; Knauer SK; Stauber RH
Oncogene; 2016 Jun; 35(26):3351-64. PubMed ID: 26657154
[TBL] [Abstract][Full Text] [Related]
8. Cell-based analysis of structure-function activity of threonine aspartase 1.
Bier C; Knauer SK; Klapthor A; Schweitzer A; Rekik A; Krämer OH; Marschalek R; Stauber RH
J Biol Chem; 2011 Jan; 286(4):3007-17. PubMed ID: 21084304
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of plant asparaginase.
Michalska K; Bujacz G; Jaskolski M
J Mol Biol; 2006 Jun; 360(1):105-16. PubMed ID: 16725155
[TBL] [Abstract][Full Text] [Related]
10. Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis.
Dong Y; Van Tine BA; Oyama T; Wang PI; Cheng EH; Hsieh JJ
Cell Res; 2014 Nov; 24(11):1354-66. PubMed ID: 25267403
[TBL] [Abstract][Full Text] [Related]
11. The importin-alpha/nucleophosmin switch controls taspase1 protease function.
Bier C; Knauer SK; Docter D; Schneider G; Krämer OH; Stauber RH
Traffic; 2011 Jun; 12(6):703-14. PubMed ID: 21418451
[TBL] [Abstract][Full Text] [Related]
12. Bioassays to monitor Taspase1 function for the identification of pharmacogenetic inhibitors.
Knauer SK; Fetz V; Rabenstein J; Friedl S; Hofmann B; Sabiani S; Schröder E; Kunst L; Proschak E; Thines E; Kindler T; Schneider G; Marschalek R; Stauber RH; Bier C
PLoS One; 2011; 6(5):e18253. PubMed ID: 21647428
[TBL] [Abstract][Full Text] [Related]
13. Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression.
Hsieh JJ; Cheng EH; Korsmeyer SJ
Cell; 2003 Oct; 115(3):293-303. PubMed ID: 14636557
[TBL] [Abstract][Full Text] [Related]
14. Design, syntheses, and evaluation of Taspase1 inhibitors.
Lee JT; Chen DY; Yang Z; Ramos AD; Hsieh JJ; Bogyo M
Bioorg Med Chem Lett; 2009 Sep; 19(17):5086-90. PubMed ID: 19631530
[TBL] [Abstract][Full Text] [Related]
15. A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth.
Chen DY; Lee Y; Van Tine BA; Searleman AC; Westergard TD; Liu H; Tu HC; Takeda S; Dong Y; Piwnica-Worms DR; Oh KJ; Korsmeyer SJ; Hermone A; Gussio R; Shoemaker RH; Cheng EH; Hsieh JJ
Cancer Res; 2012 Feb; 72(3):736-46. PubMed ID: 22166309
[TBL] [Abstract][Full Text] [Related]
16. Taspase1 processing alters TFIIA cofactor properties in the regulation of TFIID.
Malecová B; Caputo VS; Lee DF; Hsieh JJ; Oelgeschläger T
Transcription; 2015; 6(2):21-32. PubMed ID: 25996597
[TBL] [Abstract][Full Text] [Related]
17. Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia.
Zhao Z; Wang L; Volk AG; Birch NW; Stoltz KL; Bartom ET; Marshall SA; Rendleman EJ; Nestler CM; Shilati J; Schiltz GE; Crispino JD; Shilatifard A
Genes Dev; 2019 Jan; 33(1-2):61-74. PubMed ID: 30573454
[TBL] [Abstract][Full Text] [Related]
18. Allosteric inhibition of Taspase1's pathobiological activity by enforced dimerization in vivo.
Bier C; Knauer SK; Wünsch D; Kunst L; Scheiding S; Kaiser M; Ottmann C; Krämer OH; Stauber RH
FASEB J; 2012 Aug; 26(8):3421-9. PubMed ID: 22623586
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure and autoactivation pathway of the precursor form of human tripeptidyl-peptidase 1, the enzyme deficient in late infantile ceroid lipofuscinosis.
Guhaniyogi J; Sohar I; Das K; Stock AM; Lobel P
J Biol Chem; 2009 Feb; 284(6):3985-97. PubMed ID: 19038967
[TBL] [Abstract][Full Text] [Related]
20. A Bivalent Supramolecular GCP Ligand Enables Blocking of the Taspase1/Importin α Interaction.
Höing A; Zimmermann A; Moews L; Killa M; Heimann M; Hensel A; Voskuhl J; Knauer SK
ChemMedChem; 2022 Jan; 17(1):e202100640. PubMed ID: 34623765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
